Valneva initiates Phase 1/2 clinical study of inactivated, adjuvanted COVID-19 vaccine candidate

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. VLA2001 leverages the manufacturing platform of Valneva's licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news